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Background
The pharmacotherapy of psychiatric disorders exhibits
wide variability in therapeutic response with little scien-
tific guidance for treatment on a patient-by-patient basis.
Drug treatment of psychiatric disorders is troubled by
severe adverse effects, low compliance and lack of efficacy
in about 30% of patients.
Materials and methods
This article aims to review the implications of pharmaco-
genetics for clinical psychiatry; these are discussed in the
context of environmental and sociocultural factors.
Results
Pharmacogenetics and pharmacogenomics deal with the
genetic basis underlying variable drug response in individ-
ual patients. The individual differences in therapeutic and
adverse effects of psychotropic drugs are largely deter-
mined by genetic factors. Recent advances in pharmacoge-
netics have highlighted the potential utility in predicting
metabolic phenotypes, risks for side-effects and likeli-
hood of drug response for the individual patient. This
approach has clear implications for the discovery of psy-
chiatric disease-associated genes as well as for the devel-
opment of safer, more efficacious psychiatric drugs.
Although the advances of pharmacogenetics may have
many benefits in clinical practice, the importance of non-
genetic factors must also be considered as cultural and
environmental factors significantly impinge on response
to medications.
Discussion
Current pharmacotherapies for psychiatric disorders are
generally incompletely effective. Many patients do not
respond well or suffer adverse reactions to these drugs,
which can result in poor patient compliance and poor
treatment outcome. All of this will lead to novel
approaches in drug discovery, an individualized applica-
tion of drug therapy, and new insights into disease pre-
vention.
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